Literature DB >> 12459636

Clonal analysis and mutations in the PTEN and the K-ras genes in endometrial hyperplasia.

Hongbo Sun1, Takayuki Enomoto, Kenneth R Shroyer, Keiichiro Ozaki, Masami Fujita, Yutaka Ueda, Ryuichi Nakashima, Chie Kuragaki, Gaiko Ueda, Yuji Murata.   

Abstract

The patterns of X chromosome inactivation and mutations of PTEN and K-ras were evaluated in cases of endometrial hyperplasia to determine the presence of potentially premalignant neoplastic versus polyclonal benign cell populations. Endometrial glandular epithelial cells were collected by laser capture microdissection, and genomic DNAs were extracted. Following treatment with the methylation sensitive restriction endonuclease Hha I, polymerase chain reaction amplification was performed targeting a highly polymorphic short tandem repeat of the human androgen receptor gene (HUMARA). PTEN and K-ras gene mutations were evaluated by analysis of single-strand conformation polymorphism. Two pathologists performed histologic diagnosis of the lesions independently. Monoclonal composition was demonstrated in 13 of 15 (87%) endometrial hyperplasias with atypia and 17 of 31 (55%) complex hyperplasias without atypia. Cytological atypia is significantly associated with the clonal status of the endometrial hyperplasia (13/15 vs 17/31, P = 0.049). In contrast, all 14 normal endometrial tissue samples were polyclonal. PTEN gene mutations were detected in 4 of 13 (30%) monoclonal endometrial hyperplasias with atypia and 2 of 17 (12%) monoclonal endometrial hyperplasias without atypia but were not detected in polyclonal endometrial hyperplasias, with or without atypia. K-ras gene mutations were present in 3 of 13 (23%) monoclonal endometrial hyperplasias with atypia but not in 2 cases of polyclonal endometrial hyperplasia with atypia or in 26 cases of endometrial hyperplasia without atypia. K-ras mutation is thus significantly more frequently found in endometrial hyperplasias with atypia than those without atypia (3/15 vs 0/31, P = 0.030). This study indicates that most cases of endometrial hyperplasia with atypia and a high proportion of cases of endometrial hyperplasias without atypia originate from a single progenitor cell, possibly as a result of genetic alterations, rather than as a result of benign reactive processes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12459636     DOI: 10.1097/00019606-200212000-00003

Source DB:  PubMed          Journal:  Diagn Mol Pathol        ISSN: 1052-9551


  9 in total

Review 1.  Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.

Authors:  Lisa M Butler; Ylenia Perone; Jonas Dehairs; Leslie E Lupien; Vincent de Laat; Ali Talebi; Massimo Loda; William B Kinlaw; Johannes V Swinnen
Journal:  Adv Drug Deliv Rev       Date:  2020-07-23       Impact factor: 15.470

2.  Alteration of the k-ras gene expression in atypical and nonatypical hyperplastic endometrium.

Authors:  Narges Izadi-Mood; Soheila Sarmadi; Behzad Rostamnasl
Journal:  Iran J Cancer Prev       Date:  2013

3.  KDM5B Is Essential for the Hyperactivation of PI3K/AKT Signaling in Prostate Tumorigenesis.

Authors:  Guoliang Li; Thanigaivelan Kanagasabai; Wenfu Lu; Mike R Zou; Shang-Min Zhang; Sherly I Celada; Michael G Izban; Qi Liu; Tao Lu; Billy R Ballard; Xinchun Zhou; Samuel E Adunyah; Robert J Matusik; Qin Yan; Zhenbang Chen
Journal:  Cancer Res       Date:  2020-08-31       Impact factor: 12.701

Review 4.  Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification.

Authors:  Sigurd F Lax
Journal:  Virchows Arch       Date:  2004-01-28       Impact factor: 4.064

Review 5.  The endometrial hyperplasias revisited.

Authors:  Efthimios Sivridis; Alexandra Giatromanolaki
Journal:  Virchows Arch       Date:  2008-08-23       Impact factor: 4.064

6.  Clonality analysis suggests that STK11 gene mutations are involved in progression of lobular endocervical glandular hyperplasia (LEGH) to minimal deviation adenocarcinoma (MDA).

Authors:  Akiko Takatsu; Tsutomu Miyamoto; Chiho Fuseya; Akihisa Suzuki; Hiroyasu Kashima; Akiko Horiuchi; Keiko Ishii; Tanri Shiozawa
Journal:  Virchows Arch       Date:  2013-05-04       Impact factor: 4.064

7.  Molecular mechanisms of tamoxifen-associated endometrial cancer (Review).

Authors:  Rong Hu; Leena Hilakivi-Clarke; Robert Clarke
Journal:  Oncol Lett       Date:  2015-02-12       Impact factor: 2.967

8.  Genetic ablation of FASN attenuates the invasive potential of prostate cancer driven by Pten loss.

Authors:  Débora C Bastos; Caroline F Ribeiro; Thomas Ahearn; Jéssica Nascimento; Hubert Pakula; John Clohessy; Lorelei Mucci; Thomas Roberts; Silvio M Zanata; Giorgia Zadra; Massimo Loda
Journal:  J Pathol       Date:  2020-12-11       Impact factor: 7.996

9.  K-ras mutation in the endometrium of tamoxifen-treated breast cancer patients, with a comparison of tamoxifen and toremifene.

Authors:  T Hachisuga; H Tsujioka; S Horiuchi; T Udou; M Emoto; T Kawarabayashi
Journal:  Br J Cancer       Date:  2005-03-28       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.